Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6006492 | Clinical Neurology and Neurosurgery | 2014 | 5 Pages |
Abstract
Only 20% of patients with residual tumor developed recurrent disease over a median follow up of 23.1 months. This recurrence rate may be an important consideration in cases where gross total resection is not feasible. Preferentially operating from the right does not seem to influence the location of residual tumor.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Imithri Bodhinayake, Malte Ottenhausen, Michael A. Mooney, Kartik Kesavabhotla, Paul Christos, Justin T. Schwarz, John A. Boockvar,